{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T12:25:55Z","timestamp":1784031955284,"version":"3.55.0"},"reference-count":40,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Surgical Clinics of North America"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1016\/j.suc.2024.10.003","type":"journal-article","created":{"date-parts":[[2025,1,6]],"date-time":"2025-01-06T03:58:38Z","timestamp":1736135918000},"page":"385-404","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Diagnosis and Treatment of Extraintestinal Manifestations of Inflammatory Bowel Disease"],"prefix":"10.1016","volume":"105","author":[{"given":"Abhinav","family":"Gupta","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.suc.2024.10.003_bib1","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1080\/17474124.2019.1574569","article-title":"Extraintestinal manifestations in inflammatory bowel disease - epidemiology, genetics, and pathogenesis","volume":"13","author":"Greuter","year":"2019","journal-title":"Expet Rev Gastroenterol Hepatol"},{"issue":"2","key":"10.1016\/j.suc.2024.10.003_bib2","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1093\/ibd\/izad061","article-title":"Prevalence of extraintestinal manifestations in inflammatory bowel disease: a systematic review and meta-analysis","volume":"30","author":"Kilic","year":"2024","journal-title":"Inflamm Bowel Dis"},{"issue":"1","key":"10.1016\/j.suc.2024.10.003_bib3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/ecco-jcc\/jjad108","article-title":"Ecco guidelines on extraintestinal manifestations in inflammatory bowel disease","volume":"18","author":"Gordon","year":"2024","journal-title":"J\u00a0Crohns Colitis"},{"issue":"8","key":"10.1016\/j.suc.2024.10.003_bib4","doi-asserted-by":"crossref","first-page":"2100","DOI":"10.1038\/ajg.2009.190","article-title":"Distribution and manifestations of inflammatory bowel disease in Asians, Hispanics, and African americans: a systematic review","volume":"104","author":"Hou","year":"2009","journal-title":"Am J Gastroenterol"},{"issue":"5","key":"10.1016\/j.suc.2024.10.003_bib5","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1093\/ecco-jcc\/jjy191","article-title":"The pathogenesis of extraintestinal manifestations: implications for IBD research, diagnosis, and therapy","volume":"13","author":"Hedin","year":"2019","journal-title":"J\u00a0Crohns Colitis"},{"issue":"12","key":"10.1016\/j.suc.2024.10.003_bib6","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1002\/ibd.20942","article-title":"Musculoskeletal manifestations of inflammatory bowel disease","volume":"15","author":"Bourikas","year":"2009","journal-title":"Inflamm Bowel Dis"},{"issue":"2","key":"10.1016\/j.suc.2024.10.003_bib7","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1002\/rai2.12039","article-title":"Inflammatory bowel disease-related periostosis","volume":"2","author":"Yuan","year":"2022","journal-title":"Rheumatology & autoimmunity (Print)"},{"key":"10.1016\/j.suc.2024.10.003_bib8","article-title":"Ulcerative colitis with lead pipe appearance and arthropathy","author":"Dixon","year":"2011","journal-title":"Radiopaedia"},{"key":"10.1016\/j.suc.2024.10.003_bib9","author":"Ashman"},{"issue":"11","key":"10.1016\/j.suc.2024.10.003_bib10","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1111\/apt.14606","article-title":"Systematic review and meta-analysis: association between acetaminophen and non-steroidal anti-inflammatory drugs (NSAIDs) and Risk of Crohn\u2019s disease and ulcerative colitis exacerbation","volume":"47","author":"Moninuola","year":"2018","journal-title":"Aliment Pharmacol Ther"},{"issue":"8","key":"10.1016\/j.suc.2024.10.003_bib11","first-page":"e17191","article-title":"Mucocutaneous manifestations of inflammatory bowel disease","volume":"13","author":"Alvarez-Payares","year":"2021","journal-title":"Cur\u0113us (Palo Alto, CA)"},{"issue":"1","key":"10.1016\/j.suc.2024.10.003_bib13","doi-asserted-by":"crossref","first-page":"16","DOI":"10.33235\/wpr.30.1.16-23","article-title":"Pyoderma gangrenosum: a review of the clinical, mechanistic and therapeutic landscape","volume":"30","author":"Flora","year":"2022","journal-title":"Wound practice & research"},{"key":"10.1016\/j.suc.2024.10.003_bib14","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1016\/j.jaad.2016.05.044","article-title":"Clinical features, causes, treatments, and outcomes of peristomal pyoderma gangrenosum (PPG) in 44 patients: the Mayo Clinic experience, 1996 through 2013","volume":"75","author":"Barbosa","year":"2016","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.suc.2024.10.003_bib15","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1111\/apt.15766","article-title":"Risk factors and treatment outcomes of peristomal pyoderma gangrenosum in patients with inflammatory bowel disease","volume":"51","author":"Wang","year":"2020","journal-title":"Aliment Pharmacol Ther"},{"issue":"2","key":"10.1016\/j.suc.2024.10.003_bib16","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1007\/s12016-012-8351-x","article-title":"Autoinflammatory skin disorders in inflammatory bowel diseases, pyoderma gangrenosum and sweet\u2019s syndrome: a comprehensive review and disease classification criteria","volume":"45","author":"Marzano","year":"2013","journal-title":"Clin Rev Allergy Immunol"},{"key":"10.1016\/j.suc.2024.10.003_bib17","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1007\/DCR.0b013e31819accc6","article-title":"Early diagnosis and early corticosteroid administration improves healing of peristomal pyoderma gangrenosum in inflammatory bowel disease","volume":"52","author":"Funayama","year":"2009","journal-title":"Dis Colon Rectum"},{"key":"10.1016\/j.suc.2024.10.003_bib18","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1016\/j.jaad.2017.12.049","article-title":"Diagnosis and management of peristomal pyoderma gangrenosum: a systematic review","volume":"78","author":"Afifi","year":"2018","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"9","key":"10.1016\/j.suc.2024.10.003_bib19","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1001\/jamadermatol.2019.0891","article-title":"Association of hidradenitis suppurativa with inflammatory bowel disease: a systematic review and meta-analysis","volume":"155","author":"Chen","year":"2019","journal-title":"JAMA dermatology (Chicago, Ill)"},{"issue":"2","key":"10.1016\/j.suc.2024.10.003_bib20","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/S0161-6420(84)34322-6","article-title":"Primary, secondary, and coincidental ocular complications of Crohn\u2019s disease","volume":"91","author":"Knox","year":"1984","journal-title":"Ophthalmology"},{"key":"10.1016\/j.suc.2024.10.003_bib21","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1093\/ibd\/izad061","article-title":"Prevalence of extraintestinal manifestations in inflammatory bowel disease: a systematic review and meta-analysis","volume":"30","author":"Kilic","year":"2024","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.suc.2024.10.003_bib22","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1097\/00054725-200403000-00012","article-title":"Ocular manifestations of inflammatory bowel disease","volume":"10","author":"Mintz","year":"2004","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.suc.2024.10.003_bib23","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1001\/archopht.1997.01100150063010","article-title":"Uveitis associated with inflammatory bowel disease compared with uveitis associated with spongyloarthroapthy","volume":"115","author":"Lyons","year":"1997","journal-title":"Arch Opthalmol"},{"key":"10.1016\/j.suc.2024.10.003_bib24","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1111\/j.1572-0241.2002.05514.x","article-title":"Treatment of acute uveitis associated with Crohn\u2019s disease and sacroiliitis with infliximab","volume":"97","author":"Fries","year":"2002","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.suc.2024.10.003_bib25","doi-asserted-by":"crossref","first-page":"403","DOI":"10.3109\/09273940903072443","article-title":"Clinical review: anti-TNF alpha therapies in uveitis: perspective on 5 years of clinical experience","volume":"17","author":"Sharma","year":"2009","journal-title":"Ocul Immunol Inflamm"},{"key":"10.1016\/j.suc.2024.10.003_bib26","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1097\/ICU.0b013e3282f03d42","article-title":"Biologics in the treatment of uveitis","volume":"19","author":"Imrie","year":"2007","journal-title":"Curr Opin Ophthalmol"},{"issue":"2","key":"10.1016\/j.suc.2024.10.003_bib27","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1002\/ibd.20196","article-title":"Biologic therapy in the management of extraintestinal manifestations of inflammatory bowel disease","volume":"13","author":"Barrie","year":"2007","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.suc.2024.10.003_bib28","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1076\/ocii.11.2.131.15919","article-title":"Methotrexate as a first-line corticosteroid-sparing therapy in a cohort of uveitis and scleritis","volume":"11","author":"Kapan-Messas","year":"2003","journal-title":"Ocul Immunol Inflamm"},{"key":"10.1016\/j.suc.2024.10.003_bib29","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1001\/archopht.123.7.903","article-title":"A\u00a0prospective trial of infliximab therapy for refractory uveitis: preliminary safety and efficacy outcomes","volume":"123","author":"Suhler","year":"2005","journal-title":"Arch Opthalmol"},{"key":"10.1016\/j.suc.2024.10.003_bib30","doi-asserted-by":"crossref","first-page":"1832","DOI":"10.1093\/ibd\/izaa359","article-title":"Ocular manifestations of inflammatory bowel disease","volume":"27","author":"Shah","year":"2021","journal-title":"Inflamm Bowel Dis"},{"issue":"46","key":"10.1016\/j.suc.2024.10.003_bib31","doi-asserted-by":"crossref","first-page":"7227","DOI":"10.3748\/wjg.v11.i46.7227","article-title":"Extraintestinal manifestations in inflammatory bowel disease","volume":"11","author":"Danese","year":"2005","journal-title":"World J Gastroenterol"},{"issue":"suppl 1","key":"10.1016\/j.suc.2024.10.003_bib32","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1159\/000502816","article-title":"Therapies in inflammatory bowel disease in patients with extraintestinal manifestations","volume":"101","author":"Juillerat","year":"2020","journal-title":"Digestion"},{"issue":"12","key":"10.1016\/j.suc.2024.10.003_bib33","doi-asserted-by":"crossref","first-page":"2270","DOI":"10.1002\/ibd.22938","article-title":"Primar sclerosing cholangitis is associated with a distinct phenotype of inflammatory bowel disease","volume":"18","author":"Boonstra","year":"2012","journal-title":"Inflamm Bowel Dis"},{"issue":"9","key":"10.1016\/j.suc.2024.10.003_bib34","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1097\/MIB.0000000000000065","article-title":"Hepatobiliary manifestations of inflammatory bowel disease","volume":"20","author":"Yarur","year":"2014","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.suc.2024.10.003_bib35","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1002\/hep.23082","article-title":"High-dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis","volume":"50","author":"Lindor","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.suc.2024.10.003_bib36","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1002\/hep.510300501","article-title":"Long-term results of patients undergoing liver transplantation for primary sclerosing cholangitis","volume":"30","author":"Graziadei","year":"1999","journal-title":"Hepatology"},{"key":"10.1016\/j.suc.2024.10.003_bib37","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1016\/j.thromres.2008.04.004","article-title":"Biomarkers of altered coagulation and fibrinolysis as measures of disease activity in active inflammatory bowel disease: a gender-stratified, cohort analysis","volume":"123","author":"Shen","year":"2009","journal-title":"Thromb Res"},{"key":"10.1016\/j.suc.2024.10.003_bib38","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1023\/A:1010665807294","article-title":"Crohn\u2019s disease involving the lung: resolutio with infliximab","volume":"46","author":"Alrashid","year":"2001","journal-title":"Dig Dis Sci"},{"issue":"9","key":"10.1016\/j.suc.2024.10.003_bib39","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1046\/j.1464-410X.2002.02739.x","article-title":"Risk factors for developing renal stones in inflammatory bowel disease","volume":"89","author":"McConnell","year":"2002","journal-title":"BJU Int"},{"key":"10.1016\/j.suc.2024.10.003_bib40","doi-asserted-by":"crossref","DOI":"10.1177\/2058738419866567","article-title":"Inflammatory bowel disease: looking beyond the tract","volume":"33","author":"Chams","year":"2019","journal-title":"Int J Immunopathol Pharmacol"},{"issue":"7","key":"10.1016\/j.suc.2024.10.003_bib41","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.3899\/jrheum.111453","article-title":"Treatment with biologic agents improves the prognosis of patients with rheumatoid arthritis and amyloidosis","volume":"39","author":"Kuroda","year":"2012","journal-title":"J\u00a0Rheumatol"}],"container-title":["Surgical Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0039610924001385?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0039610924001385?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T20:36:41Z","timestamp":1751402201000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0039610924001385"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":40,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["S0039610924001385"],"URL":"https:\/\/doi.org\/10.1016\/j.suc.2024.10.003","relation":{},"ISSN":["0039-6109"],"issn-type":[{"value":"0039-6109","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Diagnosis and Treatment of Extraintestinal Manifestations of Inflammatory Bowel Disease","name":"articletitle","label":"Article Title"},{"value":"Surgical Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.suc.2024.10.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}